Low‐dose‐rate brachytherapy for prostate cancer: A 15‐year experience in Japan
Open Access
- 24 September 2019
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 27 (1), 17-23
- https://doi.org/10.1111/iju.14098
Abstract
The history of prostate brachytherapy has passed one century. In 1983, modern low‐dose‐rate prostate brachytherapy using a transrectal ultrasound‐guided procedure was introduced. In the early 1990s, low‐dose‐rate brachytherapy was introduced and rapidly spread across the USA due to its excellent oncological control, cost‐effectiveness and technically easy procedure. Since low‐dose‐rate brachytherapy was introduced in Japan (2003), over 15 years have passed. More than 43 000 patients have undergone low‐dose‐rate brachytherapy. Japanese urologists and radiation oncologists are on course with leading brachytherapists in the USA. A nationwide prospective cohort study, J‐POPS, was initiated in 2005. The J‐POPS group also provides educational programs including an annual novel training course in low‐dose‐rate brachytherapy to familiarize urologists, radiation oncologists and pathologists with the procedure. Important information on Japanese patients has accumulated, especially by the J‐POPS study group. The Japanese investigators reported excellent oncological outcomes of low‐dose‐rate brachytherapy, showing equivalent or superior efficacy to surgery in low‐ to intermediate‐risk patients, and superior efficacy in high‐risk patients using the surgery biochemical recurrence definition (prostate‐specific antigen cut‐off value of 0.2 ng/mL). Two randomized controlled studies (SHIP study: intermediate risk, and TRIP study: high risk) carried out by the J‐POPS group are ongoing, and an additional follow‐up study (J‐POPS 2 study) has been started to evaluate survival outcomes over longer follow‐up periods. Low‐dose‐rate brachytherapy is expected to provide a survival benefit, which must be confirmed by further studies with longer follow‐up periods in the future.Keywords
This publication has 50 references indexed in Scilit:
- Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline UpdateJournal of Clinical Oncology, 2017
- Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)International Journal of Clinical Oncology, 2014
- Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupBJU International, 2012
- American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapyBrachytherapy, 2012
- Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantationRadiotherapy and Oncology, 2004
- Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Laparoscopic Pelvic Lymph Node Dissection Combined with Real-time Interactive Transrectal Ultrasound Guided Transperineal Radioactive Seed Implantation of the ProstateJournal of Urology, 1995
- A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantationInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Transperineal 125 Iodine Seed Implantation in Prostatic Cancer Guided by Transrectal UltrasonographyJournal of Urology, 1983
- Retropubic Implantation of Iodine 125 in the Treatment of Prostatic CancerJournal of Urology, 1972